STOCK TITAN

Entera Bio Ltd - ENTX STOCK NEWS

Welcome to our dedicated news page for Entera Bio (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entera Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entera Bio's position in the market.

Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announces successful Phase 2 Trial results of EB613, an oral PTH tablet for osteoporosis treatment. The study showed significant gains in bone mineral density and no safety concerns. The highest dose of 2.5 mg demonstrated increased bone formation and decreased breakdown, addressing the treatment gap for osteoporosis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announces FDA's communication regarding the qualification of bone mineral density as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. The proposed Phase 3 study for EB613, Entera's lead clinical candidate, aims to meet the SABRE quantitative BMD thresholds. If successful, EB613 could be the first oral tablet osteoanabolic treatment, potentially revolutionizing osteoporosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announces positive pharmacokinetic results from its collaborative research with OPKO Health, Inc. on a long-acting GLP-2 agonist using Entera's N-Tab™ technology. The program aims to develop an oral tablet alternative for GLP-2 therapy, potentially revolutionizing treatment for patients with short bowel syndrome and related conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.79%
Tags
none
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported financial results and key updates for 2023, highlighting advancements in oral peptide programs like EB613 for osteoporosis and EB612 for hypoparathyroidism. The company aims to develop innovative treatments addressing unmet medical needs, with potential catalysts in 2024. Financially, Entera had $11.0 million in cash as of December 31, 2023, projecting operational funding until mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
-
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) has successfully regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2), ensuring continued listing on The NASDAQ Capital Market. The Company's ordinary shares maintained a minimum closing bid price of $1.00 or more for 10 consecutive business days, reaching this milestone on March 1st, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.44%
Tags
none
-
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, presenting a business overview and update by CEO Miranda Toledano. The virtual event will take place on February 13-14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company has until June 24, 2024, to meet the requirement. Failure to do so may result in delisting from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) closed a private placement, issuing and selling 7,916,879 units at $0.835 per unit, raising approximately $6.6 million in gross proceeds. The five-year warrants represent a 41% premium to the Nasdaq closing price per ordinary share on December 20, 2023, with potential additional proceeds of approximately $7.9 million if all warrants are exercised. The Company intends to use the net proceeds for general working capital purposes, extending its cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported interim data from a Phase 1 study on its oral peptide platform, displaying optimal profiles for osteoporosis treatment. The study compared EB613 with injectable PTH(1-34), showing superior bioavailability and consistent pharmacokinetic and pharmacodynamic effects. New compositions also demonstrated enhanced bioavailability and rapid PD responses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported corporate updates and financial results for Q3 2023, highlighting their oral peptide programs, including EB613 for osteoporosis and intense sports injuries, and EB612 for hypoparathyroidism. They also announced a transformative collaboration with OPKO Health, Inc. to develop GLP-2 for short bowel syndrome and oxyntomodulin for obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
Entera Bio Ltd

Nasdaq:ENTX

ENTX Rankings

ENTX Stock Data

105.73M
24.89M
19.9%
10.47%
0.25%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Fifth Floor

About ENTX

entera bio ltd. is a biotechnology company located in israel.